North Carolina Man who Developed Bladder Cancer after Taking Actos Files Lawsuit Alleging Actos Caused the Cancer
According to a study published last month in the Journal of the National Cancer Institute, long-term use of Actos was associated with an increased risk of bladder cancer.Sep 28, 2012 | Parker Waichman LLP
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Actos caused bladder cancer in a North Carolina man. The suit was filed on September 17th in the U.S. District Court for the Western District of Louisiana (Case No. 6:12-cv-2490). There, it is one of many similar cases pending in the multidistrict litigation known as In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America. Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company.
According to the Complaint, the Plaintiff took Actos from 2004 to 2012. He developed bladder cancer in 2009, and alleges that the cancer is a direct result of taking the drug. The suit alleges that the Defendants sold the drug despite knowing about the risk of bladder cancer. Among other things, the lawsuit is seeking compensation for severe mental and physical pain and suffering, permanent injuries, emotional distress, economic loss due to medical expenses and living related expenses due to a new lifestyle.
Last summer, the U.S. Food and Drug Administration (FDA) updated the label on Actos warning that use of the drug for more than one year could significantly raise the risk of bladder cancer. At around the same time, use of Actos was suspended in France and Germany because of its link to bladder cancer.
Research continues to support the association between Actos and bladder cancer. Last month, the Journal of the National Cancer Institute published a study showing that the long-term use of Actos and other thiazolidinediones (TZDs) could raise the risk of bladder cancer. The month prior, the Canadian Medical Association Journal published a study evaluating data from approximately 2.6 million people, and found that patients using Actos were 22 percent more likely to develop bladder cancer.
According to a recent article in Consumer Reports, Actos should be considered a last resort treatment for patients who have type 2 diabetes. The report pointed out that, even though the drug has gone generic, there are several other options with fewer risks, such as metformin, glipizide and glimepiride.
Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney